Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Liabilities: 2016-2025

Historic Total Liabilities for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $1.2 billion.

  • Ultragenyx Pharmaceutical's Total Liabilities fell 0.87% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 0.87%. This contributed to the annual value of $1.2 billion for FY2024, which is 2.10% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Total Liabilities stood at $1.2 billion for Q3 2025, which was up 2.29% from $1.1 billion recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Total Liabilities high stood at $1.2 billion for Q4 2024, and its period low was $540.3 million during Q2 2021.
  • For the 3-year period, Ultragenyx Pharmaceutical's Total Liabilities averaged around $1.2 billion, with its median value being $1.2 billion (2023).
  • Its Total Liabilities has fluctuated over the past 5 years, first decreased by 12.95% in 2021, then skyrocketed by 108.60% in 2022.
  • Ultragenyx Pharmaceutical's Total Liabilities (Quarterly) stood at $599.8 million in 2021, then soared by 98.88% to $1.2 billion in 2022, then grew by 1.90% to $1.2 billion in 2023, then grew by 2.10% to $1.2 billion in 2024, then declined by 0.87% to $1.2 billion in 2025.
  • Its Total Liabilities stands at $1.2 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.2 billion for Q1 2025.